EGFR突变阳性非小细胞肺癌在EGFR-TKI治疗进展后基于T790M状态的肿瘤免疫微环境与纳武利尤单抗疗效
该回顾性研究评估了25例EGFR突变阳性NSCLC患者在EGFR-TKI进展后接受纳武利尤单抗的疗效,并按T790M状态分析免疫相关因素;另在60例独立队列中验证T790M与PD-L1表达及TIL密度的关系,提示T790M阴性者可能更多获益。
要点
- 队列A中T790M阴性者中位PFS为2.1个月,T790M阳性者为1.3个月,P=0.099,HR=0.48(95%CI 0.20-1.24)。
- PD-L1≥1%者中位PFS为2.1个月,<1%者为1.3个月,P=0.084,HR=0.37(95%CI 0.10-1.21)。
- 两个队列中T790M阴性患者的PD-L1≥10%或≥50%肿瘤比例均高于T790M阳性患者。
核心结论
- EGFR突变阳性NSCLC患者中,T790M阴性者经EGFR-TKI治疗后可能比T790M阳性者更易从纳武利尤单抗获益,可能与更高的PD-L1表达水平有关。
研究设计与样本
- 回顾性评估纳武利尤单抗疗效及免疫相关因素。
- 队列A纳入25例EGFR突变阳性NSCLC患者,均为EGFR-TKI治疗进展后接受纳武利尤单抗者。
- 对EGFR-TKI耐药后获得的肿瘤标本行免疫组化检测PD-L1表达和TIL密度。
- 对肿瘤DNA行全外显子测序以识别基因变异。
- 独立队列B纳入60例患者,分析T790M状态与PD-L1表达或TIL密度的关系。
主要发现
- 队列A中,T790M阴性患者中位PFS为2.1个月,T790M阳性患者为1.3个月(P=0.099;HR=0.48,95%CI 0.20-1.24)。
- PD-L1表达≥1%患者中位PFS为2.1个月,<1%患者为1.3个月(P=0.084;HR=0.37,95%CI 0.10-1.21)。
- 以≥10%和≥50%为 cutoff 值时,PFS随PD-L1表达水平升高呈增加趋势。
- 队列A和队列B中,T790M阴性患者PD-L1≥10%或≥50%的肿瘤比例均高于T790M阳性患者。
- 纳武利尤单抗应答者的CD8+ TIL密度和非同义突变负荷显著更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR. PATIENTS AND METHODS: We identified 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab after disease progression during EGFR-TKI treatment (cohort A). Programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocyte (TIL) density in tumor specimens obtained after acquisition of EGFR-TKI resistance were determined by immunohistochemistry. Whole-exome sequencing of tumor DNA was carried out to identify gene alterations. The relation of T790M status to PD-L1 expression or TIL density was also examined in an independent cohort of 60 patients (cohort B). RESULTS: In cohort A, median progression-free survival (PFS) was 2.1 and 1.3 months for T790M-negative and T790M-positive patients, respectively (P = 0.099; hazard ratio of 0.48 with a 95% confidence interval of 0.20-1.24). Median PFS was 2.1 and 1.3 months for patients with a PD-L1 expression level of ≥1% or <1%, respectively (P = 0.084; hazard ratio of 0.37, 95% confidence interval of 0.10-1.21). PFS tended to increase as the PD-L1 expression level increased with cutoff values of ≥10% and ≥50%. The proportion of tumors with a PD-L1 level of ≥10% or ≥50% was higher among T790M-negative patients than among T790M-positive patients of both cohorts A and B. Nivolumab responders had a significantly higher CD8+ TIL density and nonsynonymous mutation burden. CONCLUSION: T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level, than are T790M-positive patients.
引用
- Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017. PMID: 28407039. doi:10.1093/annonc/mdx183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。